Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dolutegravir + Rilpivirine Switch Study (DORISS): Pilot and Noninferiority Trial Comparing Dolutegravir + Rilpivirine vs. Continued HAART (Highly Active Antiretroviral Therapy) in Patients With Plasma HIV RNA ≤ 50 Copies/mL for at Least 2 Years

NCT02069834 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT02069834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02069834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dolutegravir + Rilpivirine Switch Study (DORISS): Pilot and Noninferiority Trial Comparing Dolutegravir + Rilpivirine vs. Continued HAART (Highly Active Antiretroviral Therapy) in Patients With Plasma HIV RNA ≤ 50 Copies/mL for at Least 2 Years
Lead sponsor
Nantes University Hospital
Phase
Phase 2/3
Overall status
Withdrawn
Start date
May 31, 2014
Completion date
October 31, 2017
Enrollment
0 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

haart-treated, hiv infection, virologically controlled